{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:30:16Z","timestamp":1791322216612,"version":"4.3.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40265-025-02146-4","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:15:34Z","timestamp":1738818934000},"page":"437-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ebronucimab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2146_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.832614","author":"YT Huang","year":"2022","unstructured":"Huang YT, Ho LT, Hsu HY, et al. Efficacy and safety of proprotein convertase subtilisin\/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.832614.","journal-title":"Front Pharmacol"},{"key":"2146_CR2","unstructured":"Akeso Inc. Akeso\u2019s ebronucimab (PCSK9) approved for two indications for the treatment of hypercholesterolemia in China [media release]. 30 Sep 2024. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/akeso-s-ebronucimab-pcsk9-approved-for-two-indications-for-the-treatment-of-hypercholesterolemia-in-china\/."},{"key":"2146_CR3","unstructured":"Akeso Inc. Inusimab injection instructions: Chinese prescribing information. 2024. Accessed 9 Dec 2024."},{"issue":"Suppl_1","key":"2146_CR4","doi-asserted-by":"publisher","first-page":"A9318","DOI":"10.1161\/circ.146.suppl_1.9318","volume":"146","author":"R Chen","year":"2022","unstructured":"Chen R, Tian Z, Tang X, et al. The safety, pharmacokinetics, pharmacodynamics and immunogenicity of ebronucimab in healthy volunteers: result from a phase I, randomized, double-blind, placebo-controlled, single dose-escalation study [abstract no. 9318]. Circulation. 2022;146(Suppl_1):A9318.","journal-title":"Circulation"},{"key":"2146_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107340","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Pei Z, Chen B, et al. Ebronucimab in Chinese patients with hypercholesterolemia: a randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab. Pharmacol Res. 2024. https:\/\/doi.org\/10.1016\/j.phrs.2024.107340.","journal-title":"Pharmacol Res"},{"issue":"Suppl_1","key":"2146_CR6","doi-asserted-by":"publisher","first-page":"A10451","DOI":"10.1161\/circ.146.suppl_1.10451","volume":"146","author":"W Zhen","year":"2022","unstructured":"Zhen W, Pei Z, Chen J, et al. Efficacy and safety of ebronucimab, a monoclonal antibody against Pcsk9, in patients with hyperlipidemia: result from a phase 2, randomized, double-blind, placebo-controlled study [abstract no. 10451]. Circulation. 2022;146(Suppl_1):A10451.","journal-title":"Circulation"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02146-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T01:47:40Z","timestamp":1741571260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2146"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02146-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"11 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}